Skip to search formSkip to main contentSkip to account menu

Tafamidis meglumine

Known as: D-Glucitol, 1-Deoxy-1-(Methylamino)-, 2-(3,5-Dichlorophenyl)-6-Benzoxazolecarboxylate (1:1), D-Gluco-2,3,4,5,6-Pentahydroxy-N-Methylhexan-1-Aminium 2-(3,5-Dichlorophenyl)Benzoxazole-6-Carboxylate 
A soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Tafamidis, a non‐nonsteroidal anti‐inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow… 
Review
2017
Highly Cited
2016
Highly Cited
2016
Abstract Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid… 
Review
2016
Review
2016
There are more than 30 human proteins whose aggregation appears to cause degenerative maladies referred to as amyloid diseases or… 
Highly Cited
2013
Highly Cited
2013
Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial… 
Highly Cited
2013
Highly Cited
2013
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in… 
2013
2013
Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer… 
Highly Cited
2012
Highly Cited
2012
The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy… 
Review
2012
Review
2012
Familial amyloid polyneuropathy (FAP) is a rare condition caused by mutations of the transthyretin (TTR) gene and it is generally… 
Review
2011
Review
2011